List of Tables
Table 1. Global Psychiatric Long-acting Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Psychiatric Long-acting Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Psychiatric Long-acting Injection Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Psychiatric Long-acting Injection Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Psychiatric Long-acting Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Psychiatric Long-acting Injection Sales by Region (2020-2025) & (K Units)
Table 8. Global Psychiatric Long-acting Injection Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Psychiatric Long-acting Injection Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Psychiatric Long-acting Injection Sales Share by Manufacturers (2020-2025)
Table 12. Global Psychiatric Long-acting Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Psychiatric Long-acting Injection Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Psychiatric Long-acting Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric Long-acting Injection as of 2024)
Table 16. Global Psychiatric Long-acting Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Psychiatric Long-acting Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Psychiatric Long-acting Injection Manufacturing Base and Headquarters
Table 19. Global Psychiatric Long-acting Injection Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Psychiatric Long-acting Injection Sales by Type (2020-2025) & (K Units)
Table 23. Global Psychiatric Long-acting Injection Sales by Type (2026-2031) & (K Units)
Table 24. Global Psychiatric Long-acting Injection Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Psychiatric Long-acting Injection Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Psychiatric Long-acting Injection ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Psychiatric Long-acting Injection Sales by Application (2020-2025) & (K Units)
Table 29. Global Psychiatric Long-acting Injection Sales by Application (2026-2031) & (K Units)
Table 30. Psychiatric Long-acting Injection High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Psychiatric Long-acting Injection Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Psychiatric Long-acting Injection Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Psychiatric Long-acting Injection ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Psychiatric Long-acting Injection Growth Accelerators and Market Barriers
Table 37. North America Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Psychiatric Long-acting Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Psychiatric Long-acting Injection Growth Accelerators and Market Barriers
Table 40. Europe Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Psychiatric Long-acting Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Psychiatric Long-acting Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Psychiatric Long-acting Injection Growth Accelerators and Market Barriers
Table 45. Southeast Asia Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Psychiatric Long-acting Injection Investment Opportunities and Key Challenges
Table 47. Central and South America Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Psychiatric Long-acting Injection Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Psychiatric Long-acting Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Oakwood Labs Corporation Information
Table 51. Oakwood Labs Description and Major Businesses
Table 52. Oakwood Labs Product Models, Descriptions and Specifications
Table 53. Oakwood Labs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Oakwood Labs Sales Value Proportion by Product in 2024
Table 55. Oakwood Labs Sales Value Proportion by Application in 2024
Table 56. Oakwood Labs Sales Value Proportion by Geographic Area in 2024
Table 57. Oakwood Labs Psychiatric Long-acting Injection SWOT Analysis
Table 58. Oakwood Labs Recent Developments
Table 59. Teva Corporation Information
Table 60. Teva Description and Major Businesses
Table 61. Teva Product Models, Descriptions and Specifications
Table 62. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Teva Sales Value Proportion by Product in 2024
Table 64. Teva Sales Value Proportion by Application in 2024
Table 65. Teva Sales Value Proportion by Geographic Area in 2024
Table 66. Teva Psychiatric Long-acting Injection SWOT Analysis
Table 67. Teva Recent Developments
Table 68. MedinCell Corporation Information
Table 69. MedinCell Description and Major Businesses
Table 70. MedinCell Product Models, Descriptions and Specifications
Table 71. MedinCell Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. MedinCell Sales Value Proportion by Product in 2024
Table 73. MedinCell Sales Value Proportion by Application in 2024
Table 74. MedinCell Sales Value Proportion by Geographic Area in 2024
Table 75. MedinCell Psychiatric Long-acting Injection SWOT Analysis
Table 76. MedinCell Recent Developments
Table 77. Janssen Corporation Information
Table 78. Janssen Description and Major Businesses
Table 79. Janssen Product Models, Descriptions and Specifications
Table 80. Janssen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Janssen Sales Value Proportion by Product in 2024
Table 82. Janssen Sales Value Proportion by Application in 2024
Table 83. Janssen Sales Value Proportion by Geographic Area in 2024
Table 84. Janssen Psychiatric Long-acting Injection SWOT Analysis
Table 85. Janssen Recent Developments
Table 86. Otsuka America Pharmaceutical, Inc. Corporation Information
Table 87. Otsuka America Pharmaceutical, Inc. Description and Major Businesses
Table 88. Otsuka America Pharmaceutical, Inc. Product Models, Descriptions and Specifications
Table 89. Otsuka America Pharmaceutical, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Product in 2024
Table 91. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Application in 2024
Table 92. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Geographic Area in 2024
Table 93. Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection SWOT Analysis
Table 94. Otsuka America Pharmaceutical, Inc. Recent Developments
Table 95. Lundbeck Corporation Information
Table 96. Lundbeck Description and Major Businesses
Table 97. Lundbeck Product Models, Descriptions and Specifications
Table 98. Lundbeck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Lundbeck Recent Developments
Table 100. Eli Lilly Corporation Information
Table 101. Eli Lilly Description and Major Businesses
Table 102. Eli Lilly Product Models, Descriptions and Specifications
Table 103. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Eli Lilly Recent Developments
Table 105. Alkermes Corporation Information
Table 106. Alkermes Description and Major Businesses
Table 107. Alkermes Product Models, Descriptions and Specifications
Table 108. Alkermes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Alkermes Recent Developments
Table 110. Par Pharmaceutical Corporation Information
Table 111. Par Pharmaceutical Description and Major Businesses
Table 112. Par Pharmaceutical Product Models, Descriptions and Specifications
Table 113. Par Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Par Pharmaceutical Recent Developments
Table 115. AbbVie Corporation Information
Table 116. AbbVie Description and Major Businesses
Table 117. AbbVie Product Models, Descriptions and Specifications
Table 118. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. AbbVie Recent Developments
Table 120. Luye Pharmaceutical Corporation Information
Table 121. Luye Pharmaceutical Description and Major Businesses
Table 122. Luye Pharmaceutical Product Models, Descriptions and Specifications
Table 123. Luye Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Luye Pharmaceutical Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Psychiatric Long-acting Injection Product Picture
Figure 2. Global Psychiatric Long-acting Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Aripiprazole Long-acting Injection Product Picture
Figure 4. Haloperidol Long-acting Injection Product Picture
Figure 5. Paliperidone Long-acting Injection Product Picture
Figure 6. Risperidone Long-acting Injection Product Picture
Figure 7. Olanzapine Long-acting Injection Product Picture
Figure 8. Others Product Picture
Figure 9. Global Psychiatric Long-acting Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Schizophrenia
Figure 11. Bipolar Disorder
Figure 12. Others
Figure 13. Psychiatric Long-acting Injection Report Years Considered
Figure 14. Global Psychiatric Long-acting Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 16. Global Psychiatric Long-acting Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Psychiatric Long-acting Injection Revenue Market Share by Region (2020-2031)
Figure 18. Global Psychiatric Long-acting Injection Sales (2020-2031) & (K Units)
Figure 19. Global Psychiatric Long-acting Injection Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Psychiatric Long-acting Injection Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Psychiatric Long-acting Injection Sales Volume Market Share in 2024
Figure 22. Global Psychiatric Long-acting Injection Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Aripiprazole Long-acting Injection Revenue Market Share by Manufacturer in 2024
Figure 25. Haloperidol Long-acting Injection Revenue Market Share by Manufacturer in 2024
Figure 26. Paliperidone Long-acting Injection Revenue Market Share by Manufacturer in 2024
Figure 27. Risperidone Long-acting Injection Revenue Market Share by Manufacturer in 2024
Figure 28. Olanzapine Long-acting Injection Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Psychiatric Long-acting Injection Sales Market Share by Type (2020-2031)
Figure 31. Global Psychiatric Long-acting Injection Revenue Market Share by Type (2020-2031)
Figure 32. Global Psychiatric Long-acting Injection Sales Market Share by Application (2020-2031)
Figure 33. Global Psychiatric Long-acting Injection Revenue Market Share by Application (2020-2031)
Figure 34. North America Psychiatric Long-acting Injection Sales YoY (2020-2031) & (K Units)
Figure 35. North America Psychiatric Long-acting Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Psychiatric Long-acting Injection Sales Revenue (US$ Million) in 2024
Figure 37. North America Psychiatric Long-acting Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Psychiatric Long-acting Injection Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Psychiatric Long-acting Injection Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Psychiatric Long-acting Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Psychiatric Long-acting Injection Sales Revenue (US$ Million) in 2024
Figure 47. Europe Psychiatric Long-acting Injection Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Psychiatric Long-acting Injection Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 52. France Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Psychiatric Long-acting Injection Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Psychiatric Long-acting Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Psychiatric Long-acting Injection Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Psychiatric Long-acting Injection Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Psychiatric Long-acting Injection Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 67. India Psychiatric Long-acting Injection Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Psychiatric Long-acting Injection Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Psychiatric Long-acting Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Psychiatric Long-acting Injection Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Psychiatric Long-acting Injection Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Psychiatric Long-acting Injection Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Psychiatric Long-acting Injection Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Psychiatric Long-acting Injection Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Psychiatric Long-acting Injection Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Psychiatric Long-acting Injection Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Psychiatric Long-acting Injection Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Psychiatric Long-acting Injection Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Psychiatric Long-acting Injection Revenue (2020-2025) & (US$ Million)
Figure 88. Psychiatric Long-acting Injection Industry Chain Mapping
Figure 89. Regional Psychiatric Long-acting Injection Manufacturing Base Distribution (%)
Figure 90. Global Psychiatric Long-acting Injection Production Market Share by Region (2020-2031)
Figure 91. Psychiatric Long-acting Injection Production Process
Figure 92. Regional Psychiatric Long-acting Injection Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
